Mak et al., 1991 - Google Patents
Experimental chemotherapy of lymphatic filariasis. A reviewMak et al., 1991
View PDF- Document ID
- 6643275701687601645
- Author
- Mak J
- Navaratnam V
- Ramachandran C
- Publication year
- Publication venue
- Annals of Tropical Medicine & Parasitology
External Links
Snippet
An intense global collaborative effort under the leadership of the Steering Committee of the Filariasis Scientific Working Group of the Tropical Diseases Research Programme, World Health Organization, has brought together researchers, pharmaceutical chemists and …
- 208000005239 Filarial Elephantiasis 0 title abstract description 18
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Radad et al. | Rotenone: From modelling to implication in Parkinson’s disease | |
| Albert | Selective toxicity: the physico-chemical basis of therapy | |
| JP6899506B2 (en) | Stable cannabinoid preparation | |
| CN101563079B (en) | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy | |
| AP231A (en) | Antimalarial composition. | |
| US20140288056A1 (en) | Methods for non-toxic treatment for drug withdrawal | |
| Abo-Shehada et al. | Anthelmintic effect of levamisole, ivermectin, albendazole and fenbendazole on larval Toxocara canis infection in mice | |
| Fishman et al. | Metabolism of chlorpromazine. III. Isolation and identification of chlorpromazine-N-oxide. | |
| US20160347794A1 (en) | ANG-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same | |
| Hawking et al. | Diethylcarbamazine: a review of the literature with special reference to its pharmacodynamics, toxicity, and use in the therapy of onchocerciasis and other filarial infections | |
| Mak et al. | Experimental chemotherapy of lymphatic filariasis. A review | |
| US7709534B2 (en) | Method of treating strongyloides infections and medicaments therefor | |
| Skoutelis et al. | Aqueous humor penetration of ciprofloxacin in the human eye | |
| EP0290817B1 (en) | A use of oxetanocin for inhibiting hiv | |
| DE102013202928A1 (en) | Methods and compositions for treating cancer metastasis | |
| DE69027598T2 (en) | COMPOSITION TO REDUCE THE SIDE EFFECTS OF A MEDICINAL PRODUCT | |
| James | The effect of administration of an acetate on detoxication and therapeutic activity of sulphanilamide | |
| CN110882240B (en) | Polyphenol derivative compound 6-CEPN as therapeutic agent for acute ischemic stroke | |
| AU2021366666A9 (en) | Intranasal administration of suramin for treating nervous system disorders | |
| CA3194825A1 (en) | Administration of antipurinergic compositions for treating nervous system disorders | |
| DE3736691A1 (en) | IMMUNE REGULATOR CONTAINING OESTRADIOL DERIVATIVES | |
| DE69333266T2 (en) | COMPOSITION FOR REDUCING SIDE EFFECTS OF A MEDICINAL PRODUCT | |
| CN103113359A (en) | Silibinin diunsymsuccinate and pharmaceutical salt thereof | |
| EP1244442B1 (en) | Method for detecting nucleotide synthesis inhibitors having fewer side effects | |
| EP0152860B1 (en) | Use of cephalosporin compounds for the manufacture of a medicament for the modulation of the immunologic system |